Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    RFI – Supporting Development of Therapeutics for Rare and Neglected Diseases

    By Global Biodefense StaffNovember 29, 2016
    Biodefense RFI Market Research
    Share
    Facebook LinkedIn Reddit Email

    The National Center for Advancing Translational Sciences (NCATS) is conducting market research to determine capabilities of existing organizations that execute in vivo pharmacology studies and animal model support for the Therapeutics for Rare and Neglected Diseases (TRND) program.

    Currently, most of TRND’s in vivo pharmacology studies are conducted using a one-off approach with customized arrangements being made for each study, more likely than not, dictated by where the animal model resides. This is often met by lack of available human and other resources to conduct a well powered study to support drug development efforts in a reasonable time frame.

    The purpose of this RFI is to obtain extensive feedback on how a capable organization can effectively and efficiently coordinate resources needed to execute any given study or set of studies (potentially including animal model refinement/optimization or validation) that may become the subject of a TRND Request for Proposal (RFP).

    Potential tasks include:

    • Develop, optimize or use existing validated animal models to conduct in vivo pharmacology studies for rare disorders and neglected diseases for projects accepted into TRND’s portfolio. These models are not able to be pre-determined as needs change depending on the disease, hence, access to both small (e.g., mice, rat) and large animal models (e.g., dog, cat monkey, pig) will be needed.
    • Characterize and validate animal models that require development or further optimization/ refining prior to use for studies involving a therapeutic under development. Therapies can cover a wide range of modalities; small molecules, and biologics (ex. antibody, proteins, cell and gene therapy).
    • Conduct necessary in vivo studies in validated models to support initial programmatic requirement of efficacy verification and further product development to involve studies such as:
    • Conduct, if necessary, in vitro pharmacology studies to test therapeutics in existing, refined or newly developed ex-vivo or cell-based models of the disease.

    Further details are available via Solicitation Number: HHS-NIH-NCATS-RFI-17-001.

    NIH RFI
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBetter Surveillance Needed Against Rift Valley Fever Outbreaks
    Next Article Biodefense Headlines – December 4, 2016

    Related Stories

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.